New data shows Novo’s Wegovy and Ozempic US advertising spend outpaces Eli Lilly
Recent data reveals that Novo Nordisk’s advertising expenditure for its diabetes medications, Wegovy and Ozempic, has skyrocketed in the United States, surpassing the marketing budget